Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin

Jun 27 2014

• By Emily Hayes

Related Content

Ghosts of <em>Exubera</em> Haunt <em>Afrezza</em> As Lung Function, Cancer Concerns Weigh Heavily

Apr 14 2014

Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says

Jan 30 2006

Spin On MannKind's Four-Week Delay For Afrezza Goes Both Ways

Dec 30 2010

Pfizer Reports Lung Cancer Development In Some Exubera Users

Apr 14 2008

Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2

Jul 01 2009

Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?

Oct 14 2013

Related Companies

MannKind Corporation

Pfizer Inc.

Novo Nordisk A/S

Additional Topics

Clinical Trials Regulation

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window